Journals By Industry - Immunologic Factors

CGEN-15001, CGEN-15021 and CGEN-15091 are predicted B7/CD28-like proteins discovered using the company's Protein Family Members Discovery Platform. The company reported that in the collagen induced arthritis model of RA, treatments with either CGEN-15001...

LUTZ, Fla. -- CytoDyn Inc. (the "Company") (OTC QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, and other antibody applications, announced today that...

NEEDHAM, Mass. -- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it will host a research and development day for the investment community on Monday, January 23, 2012 at 8:30 am Eastern Time....

- Additional End-of-Phase 2 Meeting Not Required- -Company to Submit for Special Protocol Assessment- KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received guidance...

According to Pfizer and Medivation, Dimebon (latrepirdine) failed to meet either of its co-primary endpoints in the Phase III trial. Over the course of 12 months, no statistically significant improvements were noted on...

LOS ANGELES -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC.OB), an emerging biotechnology company focused on developing novel-immune-based therapies, today announced that its President and CEO, Manish Singh Ph.D., will present...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/dd25b8/bsl3_and_bsl4_agen) has announced the addition of John Wiley and Sons Ltd's new book "BSL3 and BSL4 Agents: Proteomics, Glycomics, and Antigenicity" to their offering. Edited by leading experts...

BERLIN -- JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG (Mainz, Germany), IUCT and LEITAT (Barcelona, Spain) announced today their collaboration on the joint development of an enhanced anticancer therapy...

NEEDHAM, Mass. -- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that dosing has initiated in a Phase 1 study of its hematopoietic growth factor, CDX-301, in healthy subjects. The study is being conducted...

Cold adapted and heat-labile unique Enzymes that Improve Molecular Biology TROMSO, Norway -- ArcticZymes AS announced today the formation of ArcticZymes Inc. a wholly owned subsidiary located in Plymouth Meeting, PA. The Company...

BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced updates to the U.S. Prescribing Information (PI) for ADCETRIS[TM] (brentuximab vedotin). The revised PI will include the following updated information: * A boxed...

LUTZ, Fla. -- CytoDyn Inc. (the "Company")(OTC QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency virus and other antibody applications, announced today that it...

Oral Vaccine With Patented Delivery System Controls Lethal Infectious Salmon Anemia Virus COLUMBIA, Md. -- Advanced BioNutrition Corp. (ABN), a leader in providing science-based solutions to improve health and nutrition, announced today that...

PRINCETON, N.J. -- Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced at the OneMedForum in San Francisco that patient dosing has begun...

For older adults, the seasonal flu can be very serious, even deadly ST. LOUIS -- The seasonal flu can be serious for everybody. So serious, in fact, that the Centers for Disease Control...

SANTA CLARA, Calif. & SEATTLE -- Agilent Technologies Inc. (NYSE: A) and Integrated Diagnostics today announced a strategic partnership to develop assays that detect major human diseases at very early stages to improve...

The results of this 24-week, blinded safety extension confirm that BCX4208 was generally safe and well-tolerated, and sustained sUA control over time. Patients generated healthy immune responses to a vaccine challenge at 16...

Four Patents Continue the Expansion of Company's Industry Leading Peptide Portfolio BOTHELL, Wash. -- Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced that it has been granted four new...

LOS ANGELES -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), an emerging biotechnology company focused on developing novel-immune-based therapies, announced today the pricing of an underwritten offering of 9,489,436 units, each...